Hey we need revenue and lots of it to conduct all the upcoming MANF trials...

As part of the option agreement, Amarantus has also agreed to engage Lonza via a long-term manufacturing services agreement (MSA) to produce ESS for human clinical trials and subsequent commercial distribution.


Amarantus estimates that the worldwide market for an effective treatment for Stage 3 and Stage 4 intractable severe burns exceeds $1 billion annually.


Current annual estimates in the United States show that more than $18B is spent on specialized care of patients with severe burn injuries.